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Background: Diabetes mellitus is associated with pancreatic cancer in more than 80% of the cases. Clinical, epidemiological,
and experimental data indicate that pancreatic cancer causes diabetes mellitus by releasing soluble mediators which interfere
with both beta-cell function and liver and muscle glucose metabolism.
Methods: We analysed, by matrix-assisted laser desorption ionization time of flight (MALDI-TOF), a series of pancreatic
cancer cell lines conditioned media, pancreatic cancer patients’ peripheral and portal sera, comparing them with controls and
chronic pancreatitis patients’ sera.
Results: MALDI-TOF analysis of pancreatic cancer cells conditioned media and patients’ sera indicated a low molecular weight
peptide to be the putative pancreatic cancer-associated diabetogenic factor. The sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis of tumor samples from diabetic and non-diabetic patients revealed the presence of a 1500
Da peptide only in diabetic patients. The amino acid sequence of this peptide corresponded to the N-terminal of an S-100
calcium binding protein, which was therefore suggested to be the pancreatic cancer-associated diabetogenic factor.
Conclusions: We identified a tumor-derived peptide of 14 amino acids sharing a 100% homology with an S-100 calcium
binding protein, which is probably the pancreatic cancer-associated diabetogenic factor.
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Patients with pancreatic cancer have a dismal prog-
nosis, and despite the availability of surgery and
chemo-radiotherapy, the 5-year survival does not57 (2005) 184–189
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significantly reduces the performance status of
patients not only because it rapidly metastasizes to
the loco-regional lymph nodes and distant organs, but
also because it is associated with severe cachexia and
glucose metabolic alterations [3–6]. It has been
demonstrated that pancreatic cancer cells overexpress
the glucose transporter GLUT1, which promotes an
increased glucose uptake, and increases cellular pro-
liferation and invasiveness, possibly by enhancing
MMP-2 expression [7]. However, the main glucose
metabolic alteration occurring in pancreatic cancer is
represented by diabetes mellitus, which is diagnosed
in more than 80% of the patients with this tumor [3,4].
In a series of 119 pancreatic cancer patients hospita-
lized in the Department of Medical and Surgical
Sciences from 2000 to 2004, 71 (60%) were found
to have diabetes mellitus, diagnosed on the basis of
more than two fasting glucose levels above 126 mg/dl
or on the basis of OGTT results, while 37 (31%) had
reduced glucose tolerance. The remaining 11 patients
(9%) had normal glucose tolerance, in agreement with
findings made by Isaksson et al. [8].
Pancreatic cancer-associated diabetes has the fol-
lowing features: (1) it is usually of recent onset,
being identified within a few months of the tumor
diagnosis [3,4,9]; (2) the hormonal alterations found
can be encompassed by the broad spectrum found both
in type I and type II diabetes mellitus. In fact, fasting
serum insulin levels may be significantly reduced, as
occurs in type I diabetes mellitus, but they may also be
normal or increased, as occurs in type II diabetes
mellitus [3]; (3) the response of beta cells to physio-
logical stimuli, such as glucagon or a meal, is usually
impaired [10]; (4) peripheral insulin resistance is often
found [11]; and (5) glucose tolerance ameliorates or
even returns to normal after tumor resection [4,11].
Clinical data thus indicate that there is a strong associa-
tion between pancreatic cancer and diabetes mellitus,
and that the tumor is the cause of the glucose metabo-
lism impairment found. However, the question of
whether diabetes mellitus is caused by, or is a cause
of, pancreatic cancer is still a widely debated issue,
since different epidemiological studies conducted have
yielded contradictory data. Findings made in a case–
control study which enrolled 720 cases and 720
matched controls from Italy appear to support the
hypothesis that pancreatic cancer causes diabetes mel-litus [9]. However, findings made in another case–
control study, from the United States, which enrolled
514 cases and 2047 matched controls favour to the
hypothesis that diabetes mellitus is a risk factor for
pancreatic cancer [12]. In another prospective cohort
study made in the United States, involving 35,658
participants who had an oral glucose tolerance test
(50 g) and a 25-year follow-up, it was estimated that
the risk of pancreatic cancer in men is about twofold the
risk in women, if the plasma glucose level after load is
above 11.1 mmol/l [13]. Although it cannot be ruled
out that diabetes mellitus may enhance the risk of
pancreatic cancer, several experimental studies suggest
that pancreatic cancer alters glucose metabolism, thus
favoring the onset of diabetes, by altering both beta-cell
function and glucose metabolism in peripheral tissues.2. Beta-cell function
In patients with pancreatic cancer, the C-peptide
response to glucagon or a test meal is impaired [10].
Furthermore, increased circulating levels of islet amy-
loid polypeptide (IAPP) have been described in
patients with pancreatic cancer-associated diabetes
mellitus [14,15]. This peptide, which co-localizes
and is co-secreted with insulin by pancreatic beta
cells, inhibits insulin secretion and decreases insulin
sensitivity and, in the early 1990s, IAPP was therefore
suggested to be the pancreatic cancer-associated dia-
betogenic factor [14]. However, since then, this
hypothesis has not been further confirmed, although
studies on IAPP secretion in vitro and in vivo con-
firmed that there is an altered beta-cell function in the
presence of pancreatic cancer, with isolated islets
incubated in vitro with pancreatic tumor cell condi-
tioned media being stimulated to secrete IAPP rather
than insulin [16,17]. Yet these results are contradicted
by findings made in vivo: in pancreatic cancer
patients, glucose was found to stimulate IAPP secre-
tion in the absence of diabetes, while the release of
this peptide in the bloodstream was found to be sig-
nificantly reduced in the presence of diabetes [18]. It
may therefore be concluded that pancreatic cancer
alters beta-cell function by reducing insulin secretion
after stimulation and by enhancing IAPP secretion.
Moreover, these effects are probably caused by solu-
ble mediators released by tumor cells.
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Glucose is a fundamental energy supply for all cell
types: the net energy balance deriving from the cata-
bolism of one glucose molecule is by 34 ATP mole-
cules: 2 from glycolysis and 32 from mitochondrial
oxidative phosphorylation. This fuel is so important
that its circulating concentration is maintained within
a restricted range by an exact homeostatic balance.
The liver and the skeletal muscle mass are mainly
involved in glucose homeostasis, due to the ability of
liver and skeletal muscle cells to store and release
glucose in response to the organism’s needs by the
synthesis and breakdown of glycogen. These pro-
cesses are strictly regulated by insulin and the coun-
ter-regulatory hormones, mainly glucagon. A reduced
peripheral insulin sensitivity has been described in
pancreatic cancer patients with diabetes, as well as a
reduced muscle glycogen accumulation secondary to a
reduced glycogen synthase and the enhanced activity
of glycogen phosphorylase enzymes [11,19]. Else-
where it was demonstrated by us in vitro that pan-
creatic cancer cell conditioned media reduce
glycolysis in isolated and perfused rat hepatocytes
[20,21]. When these cells are incubated with pancrea-
tic cancer cell conditioned media, they internalize
glucose as control hepatocytes, but, unlike in controls,
only a minor quantity of glucose is converted into
lactate, being shifted into the triglyceride synthesis
pathway, as evidenced by the accumulation of 1,2-
diacylglycerol. As demonstrated by ourselves and
other authors, glucose metabolism is also altered in
skeletal muscle cells [22,23]. When myoblasts are
conditioned by pancreatic cancer cell derived media,
an enhanced glucose transformation into lactate is
found. The enhanced glucose transformation into lac-
tate by pancreatic cancer conditioned myoblasts is
greater in tumors from patients with diabetes than in
tumors from those with normal glucose tolerance [23].
The glucose metabolic alterations found in the muscle
cells of patients with pancreatic cancer-associated dia-
betes mellitus appear to occur independent of insulin
signaling: insulin receptor binding, insulin receptor
tyrosine kinase activity, insulin receptor messenger
RNA, and insulin receptor substrate-1 content.
GLUT-4 and GLUT-4 mRNA were found to be nor-
mal in skeletal muscles from patients with pancreatic
cancer-associated diabetes mellitus [19]. Yet altera-tions have been described in the activities of enzymes
involved in glycogen synthesis and degradation, with
glycogen synthase being reduced and glycogen phos-
phorylase activities being increased, thus having a net
effect characterized by reduced glycogen synthesis
and increased glycogen breakdown. The alterations
in glucose metabolism found in myoblasts prepared
with pancreatic cancer conditioned media are accom-
panied by the altered expression of several genes,
some of which are over-expressed while others are
down-regulated [23]. The expression levels of genes
encoding for glycolytic enzymes (hexokinase 1,
GSK3A, glycogen phosphorylase, pyruvate kinase,
enolase 3, aldolase A, GAPDH, phosphofructoki-
nase, pyruvate dehydrogenase, isocitrate dehydrogen-
ase 2, glycogenin, isocitrate dehydrogenase 3
gamma, succinyl CoA synthetase, succinate dehydro-
genase, malate dehydrogenase 1, phosphoglycerate
mutase 2) were not altered by pancreatic cancer
conditioned media. Yet tumor conditioned media
were found to cause: (a) an overexpression of
genes involved in protein synthesis (18%), protein
catabolism (18%), RNA processing (14%), cell cycle
control (23%), and energy metabolism (27%); and
(b) a down-regulation of genes involved in protein
synthesis (27%), muscle development and contrac-
tion (33%), vesicle transport (13%), signal transduc-
tion and oxidation (20%), and energy metabolism
(7%). Two genes in particular, found to be over-
expressed in pancreatic cancer conditioned myo-
blasts, might be linked to an altered glucose
metabolism: propionyl CoA carboxylase and isoci-
trate dehydrogenase 3 beta (IDH3B). Propionyl CoA
carboxylase converts propionyl CoA derived from
methionine, isoleucine, valine, and unpaired fatty
acids into succinyl CoA, which enters the TCA
cycle. This may cause an acceleration of the TCA
cycle, which, in turn, would lead to a reduction in
muscle glycogen synthesis while ATP and NADH
accumulation inhibits pyruvate dehydrogenase, and
this might explain lactate accumulation. IDH3B con-
verts oxaloacetate into phosphoenolpyruvate, which
may be utilized for glucose synthesis. These data
might indicate that glucose metabolic alterations
encountered in pancreatic cancer conditioned myo-
blasts occur secondary to alterations in mitochondrial
energy metabolism, rather than to alterations in cyto-
plasmic glycolysis.
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Fig. 1. SDS-PAGE of pancreatic cancer tumor samples obtained
from patients with (D) or without (ND) diabetes mellitus. M=mole-
cular weight marker. The arrow indicates a peptide band of about
1500 Da evident in patients with, not in those without, diabetes
mellitus.
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In vitro studies indicate that the effects of pancrea-
tic cancer on beta cells, hepatocytes, and myoblasts
are probably mediated by soluble factors. When pan-
creatic cancer cell lines conditioned media are fractio-
nated according to different molecular weight ranges,
the metabolic effects of the entire media are repro-
duced by the fractions with a low molecular weight
(less than 10,000 Da) [21,23]. Elsewhere, in order to
better identify the molecular weight of this product,
we analysed by matrix-assisted laser desorption ioni-
zation time of flight (MALDI-TOF) a series of pan-
creatic cancer cell lines conditioned media, pancreatic
cancer patients’ peripheral and portal sera, comparing
them with non-conditioned media and control or
chronic pancreatitis patients’ sera [24,25]. Two frag-
ments were identified in four pancreatic cancer cell
lines, which were absent in the control medium: their
m/z, corresponding to the molecular mass, were 1874
and 2030 respectively. Of the range of low molecular
weight peptides detected in patients’ sera, only a fewTable 1
Main low molecular weight peptides found by MALDI-TOF in sera
from control subjects (CS), patients with pancreatic cancer (PC),
and chronic pancreatitis (CP)
m/z CS (n =10) PC (n =14) CP (n =9)
1240 7 (70%) 6 (43%) 3 (33%)
1327 0 0 3 (33%)
2013 6 (60%) 12 (86%) 7 (78%)
2030 1 (10%) 6 (43%) 3 (33%)
2134 0 4 (29%) 3 (33%)
2298 0 0 3 (33%)
2308 0 3 (21%) 0
2399 5 (50%) 12 (86%) 6 (66%)
2413 0 8 (57%) 1 (11%)
2517 0 4 (29%) 4 (44%)
2586 0 6 (43%) 1 (11%)
2727 0 11 (79%) 3 (33%)
3143 0 8 (57%) 5 (55%)
3597 0 8 (57%) 1 (11%)
3813 0 10 (71%) 3 (33%)
4068 0 6 (43%) 4 (44%)
4218 0 10 (71%) 3 (33%)
5002 4 (40%) 14 (100%) 8 (89%)
The numbers and percentages (in parentheses) of positive cases are
reported. The m/z 2030 and 2727 peptides were also found in
pancreatic cancer cell lines conditioned media, but not in noncondi-
tioned media.(those at m/z 2030 and 2727) were also detected in at
least one pancreatic cancer cell line conditioned media
(Table 1). Among the numerous peptides identified in
pancreatic cancer patients’ peripheral sera, only that at
m/z 2030 was correlated with the presence of diabetes
mellitus. We therefore suggested this peptide to be the
pancreatic cancer-associated diabetogenic factor [24].
The pattern of low molecular weight peptides in the
portal sera of pancreatic cancer patients is different
from that found in the peripheral sera and only one
peptide, at m/z 5002, was found to be positively
correlated with diabetes mellitus [25]. The 5002 m/z
peptide, present in pancreatic cancer patients’ periph-
eral sera and in the vast majority of control subjects,
was not correlated with the presence of diabetes mel-
litus. The 5002 m/z peptide produced by the neoplas-
tic pancreas may act on liver cells, altering their
glucose metabolism. A liver-derived degradation pro-
duct of this peptide, with a lower molecular weight,
might be released into the bloodstream, thus reaching
muscle cells, where it may interfere with their glucose
metabolism.
The sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis of cancer tis-
sues revealed a protein band of about 1500 Da in
samples from diabetic patients which were not present
in non-diabetics (Fig. 1). Protein sequencing revealed
that this 14 amino acid peptide was the N-terminal of
an S-100 calcium binding protein [26–29]. When the
synthetic peptide was incubated with cultured myo-
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and a reduced glucose utilization, thus suggesting that
it probably plays a significant role in the pathogenesis
of pancreatic cancer-associated diabetes mellitus.
In conclusion: (i) diabetes mellitus might be a risk
factor for pancreatic adenocarcinoma, but pancreatic
carcinoma causes diabetes mellitus; (ii) the pancreatic
cancer-associated diabetogenic factor, a low molecular
weight peptide (b10,000 Da), acts on liver and muscle
cells, and probably on beta cells; (iii) while the pan-
creatic cancer-associated diabetogenic factor may alter
the activity of glycolytic enzymes, it does not appear
to alter their transcription. Proteins involved in mito-
chondrial function, vesicle transport, and trafficking
may be alternative targets of the effects of the pan-
creatic cancer-associated diabetogenic factor; (iv) we
recently identified a tumor-derived peptide of 14
amino acids sharing a 100% homology with an S-
100 calcium binding protein, which alters glucose
metabolism in myoblasts and which is probably the
pancreatic cancer-associated diabetogenic factor.References
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